Renal Carcinoma Clinical Trial
— IMCOROfficial title:
Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)
Microphthalmia transcription factor (MiT) family translocation renal cell carcinomas (TRCC) are rare subtypes of kidney cancers, which often arise in children and young adults. TRCC are characterized by translocations affecting transcription factors: Transcription Factor Binding To Immunoglobulin Heavy Constant Mu Enhancer 3 (TFE3) and Transcription Factor EB (TFEB). Little is known about TRCC molecular heterogeneity, in particular their transcriptomic and epigenetic subtype classification. Clinical behavior of TRCC is varying with age and Tumor, Node, Metastasis (TNM) stage. However, the biological basis of this aggressiveness is poorly understood. PURPOSE: The primary goal of this study is to decipher specific alterations in aggressive TRCC, defined as cases with metastatic dissemination at diagnosis. To tackle this problem, a retrospective cohort of TRCC cases in children and young adults will be created. We will then perform integrative comprehensive multi-omics analysis of these tumors to identify genetic, epigenetic and immune biomarkers associated with metastatic behavior in a training and validation datasets. Comparison of the multi-omics data will be compared to other type of rare Kidney tumors as well as clear-cell renal cell carcinomas
Status | Not yet recruiting |
Enrollment | 600 |
Est. completion date | January 25, 2026 |
Est. primary completion date | January 25, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients treated for kidney cancer in a clinical center located in France For molecular biology study : - Patients with tumor sample available for genetic and epigenetic analysis. Tumor sample stored in Biological resource facilities and consent given from patient or from parents for the use of biological sample for biomedical research purposes. Exclusion Criteria: - Objection from patient or parents |
Country | Name | City | State |
---|---|---|---|
France | Réseau Français de Recherche sur le Cancer du Rein (UroCCR) | Bordeaux | |
France | Réseau SIOP, Hôpital Trousseau | Paris | |
France | Réseau CARARE | Rennes | |
France | Institut de cancérologie Strasbourg Europe | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
Institut de cancérologie Strasbourg Europe | Ministry of Health, France, National Cancer Institute, France |
France,
Herrscher H, Boilève A, Lindner V, Barthélémy P, Hutt É, Pierard L, Kurtz JE, Rioux-Leclercq N, Lang H, Malouf GG. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management]. Bull Cancer. 2020 Feb;107(2):272-280. doi: 10.1016/j.bulcan.2019.11.010. Epub 2020 Feb 7. Review. French. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of genetic alterations associated with TRCC aggressiveness. | Tumor aggressiveness is defined as TRCC cases with metastatic dissemination at diagnosis. Comparison of recurrent genetic aberration identified between metastatic and localized cases. | at the end of the study (36 months) | |
Secondary | Progression free survival (PFS) | Testing for association between molecular tumor features and clinico-pathological patients outcome, PFS, according to the identity of TFE fusion partner | From renal tumor diagnosis to progression or latest patient news at the end of the study (36 months) | |
Secondary | Overall survival (OS) | Testing for association between molecular tumor features and clinico-pathological patients outcome, OS, according to the identity of TFE fusion partner | From renal tumor diagnosis to death or latest patient news at the end of the study (36 months)6 months) | |
Secondary | Contribution of DNA methylation, transcriptome and immune landscape to metastatic potential | Proportion of patients with metastatic disease in each DNA methylation and messenger RNA (mRNA) cluster using hierarchical unsupervised subtype classifications | at the end of the study (36 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04718584 -
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
|
Phase 2 | |
Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
Recruiting |
NCT02928692 -
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
|
Phase 3 | |
Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03786796 -
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
|
Phase 2 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Not yet recruiting |
NCT06318871 -
Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
|
Early Phase 1 | |
Recruiting |
NCT06290427 -
Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)
|
N/A | |
Withdrawn |
NCT02370342 -
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
|
N/A | |
Recruiting |
NCT04773951 -
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
|
Phase 1 |